Proactive Investors - Run By Investors For Investors

Maculus Therpeutix developing spray to treat painful post-nasal surgery polyps

Maculus Therpeutix CEO Syed Askari sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Maculus Therpeutix is an ENT medical device/drug delivery company focused treating on complications associated with post-nasal surgery.

View full PROAC profile View Profile

Proactiveinvestors Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use